Trial Profile
Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Fludarabine; Melphalan
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 21 Sep 2023 Status changed from active, no longer recruiting to completed.
- 30 Aug 2021 Planned End Date changed from 1 Apr 2022 to 3 Aug 2023.
- 30 Aug 2021 Status changed from recruiting to active, no longer recruiting.